Kisspeptin-10 — GnRH-Axis Hypothalamic Decapeptide
Research evidence summary
also known as Metastin (45-54), Kp-10
Kisspeptin-10 is the shortest active fragment of the KISS1 gene product. What small human studies gave and found, how the response fades on continuous infusion, and what is unknown.
- Sequence
- YNWNSFGLRF-NH2 (10 aa)
- MW
- 1302.4 Da (PubChem)
- Discovered
- 2003
- Receptor
- GPR54 / KISS1R on hypothalamic GnRH neurones
- Half-life
- 3.8 minutes in men and 4.1 minutes in women (follicular and preovulatory phases), measured as immunoreactive kisspeptin after an intravenous infusion (Jayasena 2011) PubMed 21976724
Quoted from the source
plasma half-lives of kisspeptin-10 were calculated as 3.8 ± 0.3 min (men), 4.1 ± 0.4 min (follicular-phase women), and 4.1 ± 0.4 min (preovulatory-phase women)
- Routes in study
- SC, IV
What is kisspeptin-10?
Kisspeptin-10 (Kp-10) is a ten-amino-acid fragment of the KISS1 gene product, corresponding to amino acids 45 to 54 (also called metastin 45-54; PMID 34126799). Longer forms of 54, 14 and 13 amino acids exist, and all share the same ten-amino-acid C-terminal sequence (PMID 28464043). A 2011 trial described kisspeptin-10 as "the minimal kisspeptin sequence with full intrinsic bioactivity" (PMID 21632807).
The receptor came first. In 2003 two groups reported people who failed to go through puberty because of isolated hypogonadotropic hypogonadism, a deficiency of the pituitary hormones luteinising hormone (LH) and follicle-stimulating hormone (FSH). Both found GPR54 mutations (PMID 12944565; PMID 14573733); in the second, mice lacking the receptor had the same condition but responded to GnRH (gonadotropin-releasing hormone) and to gonadotropins. Kisspeptins stimulate GnRH release and so the pituitary's secretion of LH and FSH (PMID 21632807).
Half-life
In healthy volunteers given an intravenous infusion of 360 pmol/kg per minute, the plasma half-life of kisspeptin-10, measured as immunoreactive kisspeptin, was 3.8 ± 0.3 minutes in men, 4.1 ± 0.4 minutes in women in the follicular phase and 4.1 ± 0.4 minutes in women in the preovulatory phase, about 7-fold shorter than that of kisspeptin-54 (PMID 21976724). The half-life of kisspeptin-54 was 27.6 minutes in six men (PMID 16174713). In male mice the half-lives were about 4 minutes for kisspeptin-10 and about 32 minutes for kisspeptin-54 (PMID 28464043). A 2013 rat assay paper found kisspeptin-10 undetectable in rats 30 minutes after a 1.0 mg/kg intravenous bolus (PMID 23524040).
What has been given to people
All the studies below are small, short and done in research clinics. Units are as printed in each paper (µg/kg, nmol/kg, and flat nmol/h in the 2026 subcutaneous study) and are not converted.
| Study | What was given | Who | Main result |
|---|---|---|---|
| George 2011 (PMID 21632807) | Intravenous bolus of 0.01 to 3.0 µg/kg; infusions of 1.5 and 4 µg/kg per hour for up to 22.5 hours | Healthy men; 6 at 1 µg/kg, 4 per infusion rate | LH rose dose-dependently, maximal at 1 µg/kg (4.1 to 12.4 IU/litre at 30 minutes); 3 µg/kg gave a smaller response. A 22.5-hour infusion at 4 µg/kg per hour raised LH from 5.4 to 20.8 IU/litre and testosterone from 16.6 to 24.0 nmol/litre. |
| George 2013 (PMID 23153270) | Intravenous bolus of 0.3 mcg/kg; infusion of 4 mcg/kg per hour for 11 hours | 5 men with type 2 diabetes and low testosterone; 7 healthy men | LH rose after the bolus in both groups; in 4 men with diabetes the infusion raised LH and testosterone (8.5 to 11.4 nmol/litre). The authors called it proof of concept. |
| Jayasena 2011 (PMID 21976724) | Intravenous bolus, subcutaneous bolus and intravenous infusion | Healthy men and women, 4 to 5 per group | In men LH rose at doses as low as 0.3 nmol/kg and FSH at 1.0 nmol/kg. In women in the follicular phase there was no change in gonadotropins at the maximal doses of 10 nmol/kg intravenously, 32 nmol/kg subcutaneously and 720 pmol/kg per minute by infusion; in women in the preovulatory phase 10 nmol/kg intravenously raised LH and FSH. |
| Jayasena 2015 (PMID 26089302) | Intravenous infusion of 0.1, 0.3 or 1.0 nmol/kg per hour for 3 hours | Healthy men, 5 per group | Kisspeptin-10 and kisspeptin-54 gave similar LH and FSH levels; GnRH gave about 3-fold higher levels than kisspeptin-10. The authors list the small sample as a limitation. |
| Ullah 2019 (PMID 30590872) | One intravenous bolus of 1 µg/kg | Healthy men of three age groups | LH rose in all groups; testosterone rose only in the adult group. |
| Naveed 2026 (PMID 42230485) | Intravenous infusion of 12.5 mcg/kg per hour for 24 hours | 3 healthy men | LH rose five- to eightfold, peaking within 12 to 20 hours, then fell 13 to 47% from its maximum by the end of the infusion. |
| Yeung 2026 (PMID 42549827) | Subcutaneous infusions: 1.25 to 10.0 nmol/kg per hour for 8 hours; 180 nmol/h continuously for 5 days; 150 nmol/h for 8 hours daily for 12 days | 15 healthy men in a randomised, single-blinded, placebo-controlled study | Acute infusions raised LH, FSH and testosterone dose-dependently. After 5 days of continuous infusion testosterone stayed raised but gonadotropins were similar to vehicle. Daily 8-hour infusions sustained gonadotropin rises over 12 days, and a 1 nmol/kg bolus afterwards still raised them. |
| Skorupskaite 2016 (PMID 27636018) | Intravenous infusion of 4 µg/kg per hour for 7 hours, or vehicle, in a crossover, during oestradiol treatment and after 6 days of an oral neurokinin-3 receptor blocker | 10 healthy women on the blocker, with 10 untreated controls | Kisspeptin-10 increased LH secretion during the inhibitory phase, and LH stayed raised after the infusion ended. |
| Skorupskaite 2020 (PMID 32510130) | Intravenous infusion of 4 µg/kg per hour for 7 hours, or vehicle, in a randomised crossover; 8 women took the blocker for 7 days and 7 did not | 15 women with polycystic ovary syndrome | Without the blocker, kisspeptin-10 raised LH from 5.2 to 7.8 IU/litre; the LH response was preserved after the blocker. |
| Millar 2017 (PMID 29264460) | Intravenous infusion of 1.5 µg/kg per hour for 12 hours | 2 women with amenorrhoea from prolactin-secreting pituitary tumours that did not respond to cabergoline | LH, FSH, oestradiol, testosterone and inhibin B rose. The authors called it an exploratory study; it does not show a treatment effect. |
A PubMed search on 6 November 2026 for ("kisspeptin-10"[tiab] OR "kisspeptin 10"[tiab] OR "KP-10"[tiab]) AND ("Randomized Controlled Trial"[pt] OR "Clinical Trial"[pt]) returned 10 records. Seven reported studies in people (six of kisspeptin-10 and one of kisspeptin-54, PMID 16174713); the other three were a goat study, a monkey study (kisspeptin-54) and a ketamine trial that shares the abbreviation. None tested kisspeptin-10 as a treatment for infertility or for low sexual desire.
ClinicalTrials.gov, "kisspeptin", 6 November 2026: 45 records. Several from Massachusetts General Hospital name "kisspeptin 112-121", the residues that make up kisspeptin-10. Seven relevant records have posted results:
- NCT02956447, women with high prolactin: 36 started (21 given intravenous boluses, 15 subcutaneous doses every 90 minutes for 8 days) and 15 completed. The primary outcomes were the change in LH pulses over 10 hours and ultrasound evidence of follicle growth, seen in 3 participants in the subcutaneous group. No serious adverse events were listed; non-serious events included headache (5 of 21 and 2 of 15), pain of the skin (3 and 2) and upper respiratory infection (2 and 2).
- NCT04648969, hypogonadotropic hypogonadism: 18 started and 7 completed 20 intravenous boluses over 40 hours. The primary outcome was the change in LH pulse amplitude (0.35 IU/L with a spread of 0.43, before against during kisspeptin). One serious adverse event, rhabdomyolysis after completion of the study visits, is listed; the record does not say whether it was judged related to kisspeptin.
- NCT05901467, 16 people carrying infertility-related gene variants, one intravenous bolus of kisspeptin 112-121 and of GnRH: terminated (the team lost access to GnRH); no serious events and one upper respiratory infection.
- NCT04958109, intravenous kisspeptin 112-121 or placebo for 16 hours with an oral glucose tolerance test (11 started, 9 completed): the insulin sensitivity index was 517 on kisspeptin and 521 on placebo; no serious events, and non-serious events in 6 of 9 in each arm.
- NCT01667406, kisspeptin-54, not kisspeptin-10: see the next section.
- NCT02381288 and NCT02369796, TAK-448, a different kisspeptin analogue, in men with low testosterone and with hypogonadotropic hypogonadism (17 and 15 started): both were terminated by the sponsor because the primary endpoint or objective was not met, and neither lists serious events.
A recruiting trial of subcutaneous kisspeptin in hypogonadotropic hypogonadism (NCT05896293) has no results posted.
Kisspeptin-54, not kisspeptin-10
Several studies often cited for kisspeptin-10 used the longer kisspeptin-54:
- Dhillo 2005 (PMID 16174713). Six men received a 90-minute intravenous infusion of kisspeptin-54 (4 pmol/kg per minute) or saline in a crossover study. LH, FSH and testosterone rose.
- IVF. A 2017 review (PMID 28393578) calls kisspeptin-54 a promising trigger of oocyte maturation in IVF and says that further studies are desirable. The registered IVF trigger trial with posted results (NCT01667406, Imperial College, 175 enrolled) names all its groups kisspeptin-54; its primary outcome was the percentage of oocytes that matured, and serious adverse events were listed in 9 of 175, all pregnancy-related (ectopic pregnancy, miscarriage, heterotopic pregnancy and stillbirth). The groups included women at high risk of ovarian hyperstimulation syndrome. No kisspeptin-10 IVF trigger trial was found.
- Brain imaging. Comninos 2017 (PMID 28112678) compared kisspeptin-54 (1 nmol/kg per hour for 75 minutes) with vehicle in 29 healthy young men. Limbic brain activity in response to sexual and couple-bonding images rose, activity in response to negative images did not change, and negative mood fell.
- Low sexual desire. In women (PMID 36287566; 40 randomised, 32 completed both visits) and men (PMID 36735255; 37 randomised, 32 completed) with hypoactive sexual desire disorder, kisspeptin-54 at 1 nmol/kg per hour for 75 minutes changed brain activity in response to sexual stimuli. In men penile tumescence rose by up to 56% more than on placebo (secondary analysis). PubMed, kisspeptin AND (bremelanotide OR PT-141), 6 November 2026: one record, a narrative review of peptides in sexual medicine (PMID 42862021), and no trial of the two together.
Preclinical findings
Other work on kisspeptin-10 is in cells and animals and gives no human dose: less bone loss in mice (Li 2024, PMID 38346942), increased collagen content in heart muscle, a profibrotic change (Radwańska 2023, PMID 37968564), protection of cartilage cells from TNF-α-induced senescence in vitro (Qiu 2025, PMID 40400312), lower body weight and blood glucose in high-fat-fed female mice (Sridhar 2025, PMID 41301510), limited HIV-1 Tat-induced blood-brain-barrier damage in mice, using a modified form in the animal arm (Cheng 2025, PMID 40712838), and, in cell culture, 0.01 to 1 µM suppressed α-synuclein toxicity while 10 µM reduced cell viability further (Simon 2022, PMID 35563582).
Risks and unknowns
- Fading response. In men, gonadotropins were back to vehicle level after 5 days of continuous subcutaneous infusion (PMID 42549827), and LH fell 13 to 47% from its peak within a 24-hour infusion (PMID 42230485), while daily 8-hour infusions sustained the rise over 12 days.
- Sex and cycle phase. Women in the follicular phase did not respond at the maximal doses tested (PMID 21976724).
- Age. Testosterone rose after a bolus only in the adult men, not in middle-aged and older men, although LH rose in all groups (PMID 30590872).
- Hormone effects. LH, testosterone, oestradiol and inhibin B rose in the studies above; effects in people with hormone-sensitive conditions are not reported in them.
- Pituitary tumours. The authors of the two-patient study note that stimulation with hypothalamic hormones in people with existing pituitary adenomas has in rare cases been followed by bleeding within the adenoma. Their two patients, who had 5 and 6 mm prolactin-secreting adenomas, had no headache, visual disturbance or sign of adenoma bleeding on scans months later (PMID 29264460).
- Adverse events. The abstracts of the kisspeptin-10 studies in the table do not report adverse events. One registered trial lists a serious adverse event (rhabdomyolysis, NCT04648969, above). The full text of the two-patient study states there were no adverse events related to the infusion (PMID 29264460).
- Animals. In dogs given 30, 100 or 1,000 µg/kg intravenously once daily for 14 days, the authors reported no overt signs of drug-related toxicity and set 1,000 µg/kg as the no-observed-adverse-effect level (PMID 34126799). This is an animal toxicology figure, not a human dose.
- Duration. The longest schedule in the table is 12 days (PMID 42549827). Registered trials list subcutaneous dosing for 2 weeks (NCT05633966, completed, 13 enrolled; NCT05896293, recruiting), with no results posted; effects of longer exposure in people are not reported.
- FDA. FDA's page "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (content current as of 22 April 2026) lists Kisspeptin-10 in category 2 under the 503A interim policy, added 29 September 2023. Compounding is the preparation of a medicine by a pharmacist or doctor from its ingredients. FDA's entry reads: "Compounded drugs containing Kisspeptin-10 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. FDA has no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans."
- WADA. The WADA 2026 Prohibited List (in force from 1 January 2026) names "kisspeptin and its agonist analogues" under S2.2.1, testosterone-stimulating peptides in males, and S2 sits in the section of the List headed substances and methods prohibited at all times (WADA).
UK regulatory position
This site gives no legal advice or sourcing information and does not sell anything. Rules on unauthorised medicines exist in the Human Medicines Regulations 2012. Whether a particular product is a medicinal product under regulation 2 depends on its specifics, including how it is presented and how it functions. For questions about medicines speak to a GP or pharmacist; problems with a medicine can be reported to the MHRA through the Yellow Card scheme.
Frequently asked questions
Is kisspeptin-10 the same as kisspeptin-54? No. Both come from the KISS1 gene product and share the same ten-amino-acid end, but they differ in length and in how long they last: in male mice kisspeptin-54 sustained LH release far longer than kisspeptin-10, which was about 4 minutes in blood against about 32 (PMID 28464043). In healthy men a 3-hour infusion of either gave similar gonadotropin levels (PMID 26089302).
Related on this site
Regulatory and clinical status
UK status: No approved product found: a DailyMed search for kisspeptin on 3 November 2026 returned no label. Human studies are academic physiology and dose-finding studies in small groups. FDA safety statement: see Risks and unknowns.
Read what UK official sources say about medicines in our UK regulation hub and our explanation of why “research grade” does not mean safe. PeptideStacks does not make editorial sourcing recommendations within research content; any vendor links elsewhere on this page appear in a clearly-labelled sponsor block (see our conflict-of-interest disclosure).
References
Peer-reviewed sources for the claims above. Where an editor has verified study type, sample size, outcome and limitation, the citation is rendered as a card; otherwise as a plain reference. Links open PubMed or the journal DOI.
- Li Z, Yang X, Fu R. Kisspeptin-10 binding to Gpr54 in osteoclasts prevents bone loss by activating Dusp18-mediated dephosphorylation of Src. Nature communications. 2024;15(1) :1300 doi:10.1038/s41467-024-44852-9 · PMID: 38346942
- Radwańska P, Gałdyszyńska M, Piera L. Kisspeptin-10 increases collagen content in the myocardium by focal adhesion kinase activity. Scientific reports. 2023;13(1) :19977 doi:10.1038/s41598-023-47224-3 · PMID: 37968564
- Sridhar A, Khan D, Muthukumar R. Kisspeptin-10 Ameliorates Obesity-Diabetes with Diverse Effects on Ileal Enteroendocrine Cells and Pancreatic Islet Morphology in High-Fat Fed Female Mice. Biomolecules. 2025;15(11) :doi: 10.3390/biom15111591 doi:10.3390/biom15111591 · PMID: 41301510
- Cheng C, Xiong D, Zheng F. Kisspeptin-10 protects against HIV-1 Tat-induced blood-brain barrier dysfunction and neuroinflammation via RhoA/ROCK pathway. Neurotoxicology. 2025;110 :111-121 doi:10.1016/j.neuro.2025.07.008 · PMID: 40712838
- Qiu J, Chen G, Peng G. Kisspeptin-10 Protects Against TNF-α-Induced Chondrocyte Senescence via the SIRT1/p53/p21 Signaling. Journal of biochemical and molecular toxicology. 2025;39(6) :e70298 doi:10.1002/jbt.70298 · PMID: 40400312
- Simon C, Soga T, Ahemad N. Kisspeptin-10 Rescues Cholinergic Differentiated SHSY-5Y Cells from α-Synuclein-Induced Toxicity In Vitro. International journal of molecular sciences. 2022;23(9) :doi: 10.3390/ijms23095193 doi:10.3390/ijms23095193 · PMID: 35563582
- de Roux N, Genin E, Carel JC, et al.. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(19) :10972-6 doi:10.1073/pnas.1834399100 · PMID: 12944565
- Seminara SB, Messager S, Chatzidaki EE, et al.. The GPR54 gene as a regulator of puberty. The New England journal of medicine. 2003;349(17) :1614-27 doi:10.1056/NEJMoa035322 · PMID: 14573733
- Dhillo WS, Chaudhri OB, Patterson M, et al.. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. The Journal of clinical endocrinology and metabolism. 2005;90(12) :6609-15 doi:10.1210/jc.2005-1468 · PMID: 16174713
- George JT, Veldhuis JD, Roseweir AK, et al.. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. The Journal of clinical endocrinology and metabolism. 2011;96(8) :E1228-36 doi:10.1210/jc.2011-0089 · PMID: 21632807
- George JT, Veldhuis JD, Tena-Sempere M, et al.. Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. Clinical endocrinology. 2013;79(1) :100-4 doi:10.1111/cen.12103 · PMID: 23153270
- Jayasena CN, Nijher GM, Comninos AN, et al.. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. The Journal of clinical endocrinology and metabolism. 2011;96(12) :E1963-72 doi:10.1210/jc.2011-1408 · PMID: 21976724
- Jayasena CN, Abbara A, Narayanaswamy S, et al.. Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men. Human reproduction (Oxford, England). 2015;30(8) :1934-41 doi:10.1093/humrep/dev143 · PMID: 26089302
- Ullah H, Nabi G, Zubair H, et al.. Age-dependent changes in the reproductive axis responsiveness to kisspeptin-10 administration in healthy men. Andrologia. 2019;51(4) :e13219 doi:10.1111/and.13219 · PMID: 30590872
- Naveed A, Lippincott MF, Stamou M, et al.. Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men. Hormones (Athens, Greece). 2026 doi:10.1007/s42000-026-00795-y · PMID: 42230485
- Yeung AC, Phylactou M, Koysombat K, et al.. Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men. European journal of endocrinology. 2026;195(2) :206-216 doi:10.1093/ejendo/lvag134 · PMID: 42549827
- Millar RP, Sonigo C, Anderson RA, et al.. Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea. Journal of the Endocrine Society. 2017;1(11) :1362-1371 doi:10.1210/js.2017-00328 · PMID: 29264460
- d'Anglemont de Tassigny X, Jayasena CN, Murphy KG, et al.. Mechanistic insights into the more potent effect of KP-54 compared to KP-10 in vivo. PloS one. 2017;12(5) :e0176821 doi:10.1371/journal.pone.0176821 · PMID: 28464043
- Comninos AN, Wall MB, Demetriou L, et al.. Kisspeptin modulates sexual and emotional brain processing in humans. The Journal of clinical investigation. 2017;127(2) :709-719 doi:10.1172/JCI89519 · PMID: 28112678
- Thurston L, Hunjan T, Ertl N, et al.. Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA network open. 2022;5(10) :e2236131 doi:10.1001/jamanetworkopen.2022.36131 · PMID: 36287566
- Mills EG, Ertl N, Wall MB, et al.. Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA network open. 2023;6(2) :e2254313 doi:10.1001/jamanetworkopen.2022.54313 · PMID: 36735255
- Kasum M, Franulić D, Čehić E, et al.. Kisspeptin as a promising oocyte maturation trigger for in vitro fertilisation in humans. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2017;33(8) :583-587 doi:10.1080/09513590.2017.1309019 · PMID: 28393578
- Terse PS, Peggins J, Seminara SB. Safety Evaluation of KP-10 (Metastin 45-54) Following once Daily Intravenous Administration for 14 Days in Dog. International journal of toxicology. 2021;40(4) :337-343 doi:10.1177/10915818211023459 · PMID: 34126799
- Vasylieva V, West A, Karpman E. Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review. Sexual medicine reviews. 2026;14(4) doi:10.1093/sxmrev/qeag078 · PMID: 42862021
- Skorupskaite K, George JT, Veldhuis JD, et al.. Interactions Between Neurokinin B and Kisspeptin in Mediating Estrogen Feedback in Healthy Women. The Journal of clinical endocrinology and metabolism. 2016;101(12) :4628-4636 doi:10.1210/jc.2016-2132 · PMID: 27636018
- Skorupskaite K, George JT, Veldhuis JD, et al.. Kisspeptin and neurokinin B interactions in modulating gonadotropin secretion in women with polycystic ovary syndrome. Human reproduction (Oxford, England). 2020;35(6) :1421-1431 doi:10.1093/humrep/deaa104 · PMID: 32510130
- Liu Z, Ren C, Jones W, et al.. LC-MS/MS quantification of a neuropeptide fragment kisspeptin-10 (NSC 741805) and characterization of its decomposition product and pharmacokinetics in rats. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2013;926 :1-8 doi:10.1016/j.jchromb.2013.02.027 · PMID: 23524040
- Correction (2026-11-06): Corrected 6 November 2026 after a dose and citation audit: dosing text was replaced by a table of published studies; the half-life and LH-fading claims were corrected; IVF, imaging and desire studies were re-attributed to kisspeptin-54; FDA's safety statement was added; legal text was replaced.
If you spot an error or have new evidence to suggest, please use our corrections policy.
Research combinations referencing Kisspeptin-10
Combination evidence reviews on this site that include Kisspeptin-10 as one of their peptides.
Continue reading
GnRH (Gonadotropin-Releasing Hormone)
A hypothalamic decapeptide released in pulses that drives pituitary LH and FSH secretion, governing the entire hypothalamic-pituitary-gonadal axis.
GPR54 / KISS1R
Kisspeptin receptor on hypothalamic GnRH neurons. Loss-of-function variants cause failure or delay of puberty in people, which is how its role in reproduction was identified.